Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
about
Heat shock proteins as danger signals for cancer detectionMaximizing the Therapeutic Potential of HSP90 InhibitorsAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersA phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsInhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerHeat shock protein 90 inhibition: rationale and clinical potential.Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosusSmall molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiationPreclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.Quantitatively integrating molecular structure and bioactivity profile evidence into drug-target relationship analysisA physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer.Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancerPotent antitrypanosomal activities of heat shock protein 90 inhibitors in vitro and in vivo.Efficiency of AUY922 in mice with adult T-cell leukemia/lymphomaRecruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor.Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.Radioprotective effects of oral 17-dimethylaminoethylamino-17-demethoxygeldanamycin in mice: bone marrow and small intestine.Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.Unfolded protein response in cancer: the physician's perspectiveThe role of heat shock protein 90 in modulating ischemia-reperfusion injury in the kidney.Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.Overexpression of DJ-1 and HSP90α, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers.First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants.Hsp90 and angiogenesis in bone disorders--lessons from the avian growth plate.
P2860
Q24273349-71232A03-BF97-4AA6-BFFB-A99983E3BFA4Q26798318-18CAAA02-96DB-4825-890F-9C667DD2A1ACQ27022514-A485F0B1-0479-4C5B-9BE3-9DE3550222E4Q28304273-F1AC52B8-17C2-4264-9CB9-3688B8586EE0Q28541342-15EE871D-15A5-45A7-BC24-4CD6B1C8B286Q30418761-C749087B-95C7-4245-8681-504599091A52Q33577386-33572CD9-C891-407A-93D4-309BC209B801Q33688577-8EA0304B-EF0F-415B-AA88-460BB2855677Q33825349-12FE601A-E672-4BDE-B29D-A2888178E37BQ34120364-C50608F7-AA7C-4AAA-88EF-D54F0F11D4A9Q34258626-726CFC00-69F7-48A9-A83E-A2D8FC12BD92Q34570770-971F54A0-DFC9-4B68-BB3B-1FECD0309B78Q34636437-0E2F5776-7980-4E53-8DFC-41E16F8DB1D9Q35166674-0887CCDC-63F3-41C6-89FE-4F7223D6168EQ35546764-EF012579-3D03-409C-BB4F-FFCA98318993Q36060751-B5749C26-1047-4A6E-88AF-392DFF40BDDFQ36074307-5A5D9732-CD6B-4F96-9D3F-05FA433BB254Q36490656-3EB584E7-9001-4590-A692-AB00A7BB017DQ36974927-16CCDB60-CD9D-43CE-B1C6-100A0A1BB927Q37001967-F66FED77-B57C-4305-9A6F-1AD81475055AQ37213835-D262C2EF-48B7-4B88-9EBA-B7C0C2C9B1AEQ37286051-71B1A34C-25A7-4966-8063-646074482E17Q37365958-6300BB11-D3F4-43F3-9909-C1CF32A925FDQ37717405-5760E5E1-309E-459D-83C9-8D3D3B62D2E9Q37846249-A851CAA6-FC93-4A8D-82C6-31223CB61511Q38033199-E115FBEB-A149-4D82-B49E-16823465B134Q38769817-0F6DA74D-AEC0-4B10-816E-589E35095EA3Q38834735-386CD6E8-5ABB-4B89-B40A-D99DA3191AC4Q41660465-B34ABC3C-D378-4479-93E1-F64F81F641B4Q41984466-89EE943F-CE86-4474-B8AA-9D36CCBD7BC4Q48238685-E842EFFF-1B52-4A6B-ACA9-90E889856890Q52327617-94B82290-E701-46D7-9F86-30EF6CC08ECBQ54590776-68E70981-D4E9-44BD-93F9-172B1BE8EE61
P2860
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I pharmacokinetic and ph ...... nts with advanced solid tumors
@ast
Phase I pharmacokinetic and ph ...... nts with advanced solid tumors
@en
type
label
Phase I pharmacokinetic and ph ...... nts with advanced solid tumors
@ast
Phase I pharmacokinetic and ph ...... nts with advanced solid tumors
@en
prefLabel
Phase I pharmacokinetic and ph ...... nts with advanced solid tumors
@ast
Phase I pharmacokinetic and ph ...... nts with advanced solid tumors
@en
P2093
P2860
P356
P1476
Phase I pharmacokinetic and ph ...... nts with advanced solid tumors
@en
P2093
Charles Erlichman
Cynthia J TenEyck
Cynthia Naret
Julianne L Holleran
Merrill J Egorin
Ramesh K Ramanathan
S Percy Ivy
Scot C Remick
Suresh S Ramalingam
P2860
P304
P356
10.1200/JCO.2009.25.0415
P407
P577
2010-02-22T00:00:00Z